IHS Chemical Week

Regions :: Western Europe :: Sweden

Swedish drugmaker Meda rejects Mylan's bid offer

10:59 AM MDT | April 28, 2014 | Natasha Alperowicz

In the latest wave of M&A frenzy in the pharma industry, Meda (Solna, Sweden) today rejected a revised bid offer by Mylan, the largest generic-drug company in the United States. “The board hereby confirms that it has been contacted by Mylan regarding a revised, nonbinding, indicative interest to combine the two businesses. The board has convened and has decided to reject the proposal. All contacts between Meda and Mylan have been terminated without further actions. The board’s decision is based on a strong belief in the continued potential of Meda...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa